India rejects Yeda's glatiramer patent
This article was originally published in Scrip
Executive Summary
India has rejected Yeda Research and Development's patent application for a composition of glatiramer acetate, used to treat multiple sclerosis, following opposition from the domestic company Natco Pharma.